{
    "clinical_study": {
        "@rank": "116167", 
        "brief_summary": {
            "textblock": "To provide access to palbociclib to post-menopausal women with HR-positive, HER2-negative\n      advanced breast cancer who are deemed appropriate for letrozole therapy."
        }, 
        "brief_title": "Expanded Access Study Of Palbociclib In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR-Positive, Her2-Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate", 
        "completion_date": {
            "#text": "November 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Advanced Breast Cancer (Female)", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "Accepting interested sites; not yet open for participant recruitment."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Post-menopausal women 18 years of age or above with proven diagnosis of advanced\n             adenocarcinoma of the breast (locoregionally recurrent or metastatic disease)\n\n          -  ER-positive and/or PR-positive tumor based on local laboratory results\n\n          -  HER2-negative tumor based on local laboratory results\n\n          -  Patients must be appropriate candidates for letrozole therapy\n\n        Exclusion Criteria:\n\n          -  Patients who have previously participated in a palbociclib trial or who have received\n             prior treatment with any CDK inhibitor"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "May 16, 2014", 
        "id_info": {
            "nct_id": "NCT02142868", 
            "org_study_id": "A5481034"
        }, 
        "intervention": [
            {
                "description": "Palbociclib will be administered orally once a day at 125 mg/day for 21 days followed by 7 days off treatment for each 28-day cycle (Schedule 3/1)", 
                "intervention_name": "Palbociclib", 
                "intervention_type": "Drug"
            }, 
            {
                "description": "Letrozole will be administered orally at 2.5 mg once daily as continuous daily dosing schedule according to product labeling and in compliance with its local prescribing information.", 
                "intervention_name": "Letrozole", 
                "intervention_type": "Drug", 
                "other_name": "Femara"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Letrozole"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Expanded Access", 
            "Advanced Breast Cancer"
        ], 
        "lastchanged_date": "May 21, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A5481034&StudyName=Expanded%20Access%20Study%20Of%20Palbociclib%20In%20Combination%20With%20Letrozole%20As%20Treatment%20Of%20Post-Menopausal%20Women%20With%20HR-Positive%2C%20Her2-Negative%20A"
        }, 
        "official_title": "An Expanded Access Study Of Palbociclib In Combination With Letrozole As Treatment Of Post-Menopausal Women With Hormone Receptor Positive, Her2 Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate.", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Temporarily not available", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "October 2017", 
            "@type": "Anticipated"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02142868"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "N/A", 
        "study_type": "Expanded Access", 
        "verification_date": "May 2014"
    }
}